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Abstract
Aims To compare the effect of bariatric surgery on renal, chronic kidney disease (CKD) and cardiovascular (CV) outcomes
among obese patients with insulin-treated type 2 diabetes (T2D) with and without microalbuminuria (i.e., uACR > 3.0 mg/
mmol).
Methods A retrospective cohort study was conducted among 11,125 active patients with T2D from The Health Improvement
Network (THIN) database. Propensity score matching (up to 1:6 ratio) was used to identify patients who underwent bariatric
surgery (N = 131) with a non-bariatric cohort (N = 579). Follow-up was undertaken for 10 years (6487 person-years) to compare
differences in risk of cardiovascular events and in renal outcomes.
Results For the matched cohort at baseline: mean age 52 ± 13 years (60% female); weight 116 ± 25 kg, body mass index (BMI)
41 ± 9kg/m2, estimated glomerular filtration rate (eGFR); 70.4 ± 20 mL/min/1.73 m2, and median albumin-creatinine ratio
(uACR) 2.0 mg/mmol (interquartile range (IQR): 0.9–5.2 mg/mmol). Bariatric surgery was associated with a 54% reduction in
developing CKD compared to their matched non-bariatric cohort (adjusted hazard ratio [aHR]: 0.46; 95%CI: 0.24–0.85, P =
0.02). Among patients with microalbuminuria at baseline, bariatric surgery was protective against CKD (aHR: 0.42, 95%CI:
0.18–0.99, P = 0.050). eGFRwas significantly increased from baseline favouring the bariatric group during 75% of the follow-up
time (calculated mean difference between groups: 4.1 mL/min/1.73 m2; P < 0.05), especially at 5-year point (74.2 vs 67.8 mL/
min/1.73 m2; P < 0.001). However, no significant change was observed with non-fatal CVD episodes (aHR: 0.36, 95%CI: 0.11–
1.13, P = 0.079). Albumin levels were significantly reduced throughout the 2 years following the surgery (3.9 vs 4.1 g/dL, P <
0.001). uACR and total protein levels had little or no statistical association to the intervention.
Conclusion Bariatric surgery may protect patients with diabetes with or without microalbuminuria against the risk of CKD and
with a modest protective effect on non-fatal CVD risk. Bariatric surgery is also associated with improvements in overall renal
outcomes such as eGFR.
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Background
Obesity and type 2 diabetes (T2D) are major global health
problems that are intrinsically linked with adverse cardio-
renal outcomes [1, 2]. Dysfunctional adipose tissue in obe-
sity is associated with increased pro-inflammatory state,
insulin resistance, hyperglycaemia, endothelial dysfunction
and hypertension, all of which are known risk factors for the
development and progression of cardiovascular (CV) dis-
ease and chronic kidney disease (CKD) [2, 3]. Furthermore,
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many patients with T2D will require insulin treatment to
control hyperglycemia. This is relevant within the context
of diabetic kidney disease since insulin therapy is known to
induce ~ 4–9 kg weight gain in the first year of treatment [4]
while obesity per se is a significant risk factor for the ap-
pearance of proteinuria and ESRD [2]. Further, recent evi-
dence from randomised controlled trials, epidemiological
and observational studies have implicated insulin therapy
in patients with T2D with increased CV risk and mortality
[5–8]. Thus, a cohort of insulin-treated patients with T2D
represents a complex heterogenous, challenging group of
patients, many of whom have significant comorbidities
and high CKD risk. CKD is defined as an estimated glomer-
ular filtration rate (GFR) of less than 60 mL/min/1.73 m2 or
the presence of increased urinary albumin excretion
(microalbuminuria), indicated by urine albumin-to-
creatinine ratio [uACR] of 3.0–30.0 mg/mmol), or overt
proteinuria (uACR > 30.0 mg/mmol), all of which are inde-
pendent risk factors for CVand kidney disorders in the gen-
eral population and in patients with diabetes [9]. Thus,
weight loss by any means is important to improve cardio-
renal outcomes [10]. Although diet and exercise play a cru-
cial role in obesity management, lifestyle alone may not
achieve durable weight loss in the majority of patients
[11]. Bariatric surgery, therefore, has emerged as the most
effective and durable strategy for long-term weight loss in
morbidly obese individuals [12].
Despite the clear benefits of bariatric surgery onweight and
glycemic outcomes in people with T2D, the impact of bariat-
ric surgery on the development and progression of CKD or
micro-albuminuria is less clear. Previous studies have reported
improvements in uACR [13–16], which can be observed not
long after surgery [15, 16]. This is thought to be driven by
multi-factorial improvements in blood pressure, HbA1c and
BMI [15]. A further study concluded that bariatric surgery
should be offered as an early treatment for patients with
microalbuminuria or with overt proteinuria to prevent CKD
from progressing to an end-stage kidney disease (ESKD) [17].
However, many of these studies were either small case series,
not specific to people with insulin-treated diabetes, had vari-
able albuminuric state at baseline, or did not adjust for impor-
tant confounders. Conversely, inconsistent findings were re-
ported in a systematic review of the effects of bariatric surgery
on renal outcomes by Zhou et al [18], with some studies also
noting harmful effects on kidneys of obese patients who re-
ceived bariatric intervention. For example, there may be an
increased risk of kidney stones after malabsorptive bariatric
surgery, which is considered to be linked with surgery-
induced fat malabsorption [19]. Furthermore, despite weight
benefits, there are negative metabolic outcomes related to bar-
iatric intervention, such as nutritional deficiencies, reduction
in lean body mass and bone density loss, all of which are
highly relevant in patients with CKD [20].
This study aims to retrospectively explore the possible pre-
ventive effect of bariatric surgery against CKD, renal-cardio-
vascular, as well as impact on health and renal outcomes in
patients with and without microalbuminuria (i.e., uACR > 3.0
mg/mmol).
Methods
Study Design and Data Sources
This was a retrospective cohort study that used The Health
Improvement Network (THIN), a UK primary care database
with systematically computerised longitudinal and
anonymised health records from primary care physicians.
The database contains details on demographics, lifestyle char-
acteristics (e.g. alcohol use and smoking), major medical and
surgical conditions, drug utilisation and various health out-
comes of over 17 million patients, 3.1 million of which are
registered as active patients. Patients’ records were derived
from over 600 UK general practices [21]. The dataset slice
we acquired has information of active patients with insulin-
treated type 2 diabetes up to September 2017. Ethics approval
was provided to THIN by the NHS South East Multi-Centre
Research Ethics Committee (MREC). The Scientific Review
Committee (SRC) reviewed the study protocol for scientific
merit and feasibility.
Study Population
The dataset contains 11,125 adult patients (18 years and over
with no upper age limit) diagnosed with T2D who had been
prescribed with any form of insulin therapy up to September
2017. Patients’ index date was based on either the day of
bariatric surgery or, in case they had not received bariatric
intervention, the first intensification of insulin therapy.
Dataset was scanned to identify patients with no history of
insulin use or diagnosed with type 1 diabetes for possible
exclusion.
Exposure and Outcomes
Our exposure of interest is bariatric surgical intervention for
morbidly obese patients with insulin-treated T2D. The study
was exposure-based, in which patients were censored
throughout 10 years of follow-up—following the develop-
ment of primary outcome, transferred out, loss to follow-up,
or at the end of the study. Primary outcomes were patients’
survivability against diagnosed CKD events, with further
stratification to include CKD and CVD events, from a popu-
lation of patients with microalbuminuria (uACR > 3 mg/
mmol) at baseline. The risk of CKD was measured according
to observed CKD data that were reported with specific dates in
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the main THIN database. The CKD events were assessed and
reported by health professionals according to the medical
criteria used across the NHS primary health provision (GFR
< 60 or ACR > 3.5) and covered by the THIN database col-
lection system. The crude CVD events included the first oc-
currence of either acute myocardial infarction, stroke, coro-
nary heart disease, heart failure, or peripheral artery disease.
Observations of CVD events were obtained in a similar man-
ner as with events of CKD reporting system prearranged by
THIN. Secondary outcomes included likelihood of being im-
proved in eGFR, as well as health covariates, such as levels of
uACR, total protein, albumin and serum creatinine.
Covariates and Follow-up Strategy
The treatment group, those undergoing bariatric surgery and
being insulin-treated T2D from the date of surgery, was
followed up and compared with their propensity-score (PS)-
matched insulin initiators from their first insulin prescription
date up to the endpoint of the 10-year follow-up period.
Patients with diagnosed CKD or whose CVD events occurred
prior to the designated baseline point were excluded from the
primary survival estimation on each stratified element.
The baseline clinical parameters were measured at a similar
point of time according to patient’s treatment category.
Patients who underwent bariatric surgery, for instance, will
have their baseline parameters calculated1 from 90 days up
to 1 day before the surgery date. Similarly, the non-bariatric
patients will have their baseline parameters calculated via the
same time window according to their first intensification of
insulin therapy. Covariates were, then, recalculated at 6
months, and at each year point during follow-up, with a 90-
day window on every concurring point of time.
Statistical Analysis
Primary analysis was time to the risk of crude CKD events and
stratified CKD and CVD events in the PS-matched groups.
The PS model was estimated by using a logistic regression
model in order to adjust for baseline characteristics, thus,
minimising allocation bias between groups. The balance as-
sessment was made between bariatric (treated) and non-
bariatric (untreated) groups by measuring standardised differ-
ences before and after the matching procedure. The mean
from continuous covariates and proportion of categorical var-
iables between groups were examined and summarised. Each
treatment subject was matched to a maximum number of six
reference subjects at the nearest distance measured by the
estimated PS, based on the estimated treatment probabilities
[22]. Furthermore, in order to minimise distance within
matched sets, we employed calliper of width equal to 0.05
of the standard deviation of the logit of the PS, which may
improve match quality and also limited excessive numbers of
matched subjects [23]. A calliper of width of 0.2 or lower was
shown in recent research to result in optimal estimation com-
pared to higher choices of calliper use [24]. PS was included
in all Cox proportional hazards regression modelling as it was
considered a prognostic covariate.
We used the stratified log-rank test, with Kaplan-Meier
survival curves, respectively, to compare the equality between
the PS-matched groups. The absolute reduction in the proba-
bility of an event occurring within 10-year follow-up was,
thus, calculated. Marginal hazard ratios were also estimated,
which allowed the quantification of the adjusted hazard of an
event occurring in the bariatric group compared to the
matched non-bariatric group. Proportional hazards assump-
tions were confirmed through Schoenfeld residual test. Point
estimates with 95% confidence intervals (CIs) at the conven-
tional statistical significance level of 0.05 were used in the
regression models. The proportional hazards assumption was
examined by comparing the cumulative hazard plots grouped
on exposure; no violations were observed.
Missing data among covariates were managed through
multiple imputations using the predictive means matching
for continuous covariates with accounting to exposure (i.e.
bariatric), age, gender, diabetes duration, Townsend depriva-
tion status, marital status, smoking and alcohol use [25]. To
test the adequacy of our multiple imputation approach in ad-
dressing the impact of some missing data, we conducted a
sensitivity analysis wherein the primary endpoints in the im-
puted dataset were compared with the dataset with missing
values and found to be similar up to 2 years of follow-up.
This affirmed the robustness of the imputation method
employed before PS matching procedure was performed [26].
We used Student’s t test to estimate the mean changes in
continuous variables (e.g. uACR and total protein) in the PS-
matched group for 2 years of follow-up compared to their
baseline measurements. We limited these variables to 2 years
due to the heavy load of missing data beyond this point, which
restricted multiple imputation from producing reliable predic-
tions. Nonetheless, eGFR was at a predictable level up to 5
years, which made it possible to run Pearson X2 to test the
likelihood of being improved throughout 5 years from the
baseline. Wilcoxon rank-sum test was used to check differ-
ences in medians for nonparametric variables (i.e. uACR).
Statistical significance was set at a p level of 0.05. To avoid
the probability of type II error, the study was powered to 0.86
and the matched sample size of 710 was found to detect a true
difference of less than 0.1 between the two groups at 5%
significance level. The study fulfilled the STROBE criteria
for reporting observational studies. Throughout, we used
SAS Software version 9.4 in the initial dataset management
(SAS Institute, Cary, NC); Stata/SE Statistical Software
1 Average value is calculated for multiple entry records that were found during
the 90 days window for the same variable.
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version 15.1 in all carried analysis (StataCorp., College
Station, TX); and GraphPad/Prism version 8.1.0 for visualisa-
tion (La Jolla, CA).
Results
Patients’ Characteristics and Total Follow-up
From a total population of 11,125 patients with insulin-treated
T2D in THIN database, we identified 155 patients who have
had Roux-Y-gastric bypass surgical operations. The PS
matching procedure has allowed (131) bariatric patients to
be matched with up to six control subjects (579). This yielded
a total number of 710 PS-matched participants. The median
treatment duration was 10.07 years (interquartile range (IQR):
6.11–14.31 years). The median follow-up was 12.8 years
(IQR: 5.1–14.5 years) for the matched cohort, representing a
total follow-up period of 6487 person-years.
The mean age for the matched groups at baseline was 51.7
(SD 12.5) years; 59.6%were females. The mean body weight,
BMI and HbA1c level were 115.7 (SD 25.4) kg, 40.7 (SD 9.2)
kg/m2 and 71.2 (SD 18.1) mmol/mol, respectively. The mean
eGFR was 70.4 (SD 20.5) mL/min/1.73 m2, with a median
uACR of 2.0 (IQR: 0.9–5.2) mg/mmol. The baseline charac-
teristics in both bariatric and non-bariatric groups were com-
pared between the full and matched cohort with respective
standardised differences and are shown in Table 1.
Probability of Survival and Event Rate
The probability of survival for CKD in the full cohort was
significantly different between bariatric and non-bariatric
groups: at 1 year (99.2% vs 97.7%), 5 years (96.9% vs
89.9%) and 10 years (94.9% vs 80.2%) of follow-up (log-rank
test p value = 0.028). However, the estimates of CKD event
rate in the unadjusted PS matched cohort showed little or no
statistical significance of a difference throughout 10 years of
follow-up (log-rank test p value = 0.19). A total of 119 CKD
events were observed (16 vs 103) with a crude event rate of
18.3 (14.5 vs 19.1) per 1000 person-years (95%CI: 15.3–
21.9).
The difference in probability of survival for CKD in pa-
tients with microalbuminuria was statistically insignificant in
both full and matched cohorts (log-rank test: p value = 0.14
and p value = 0.24, respectively). In the matched group, a total
of 51 CKD events were observed (8 vs 43) with a crude event
rate of 22.2 (14.3 vs 25.4) per 1000 person-years (95%CI:
17.2–29.8).
The difference in probability of survival for CVD in pa-
tients with microalbuminuria was statistically insignificant in
both full and matched cohorts (log-rank test: p value = 0.28
and p value = 0.54, respectively). In the matched group, a total
of 43 CVD events were observed (10 vs 33) with a crude event
rate of 55.0 (49.5 vs 56.9) per 1000 person-years (95%CI:
40.8–74.2). Figure 1 and Table 2 summarise the observed
events, event rates and differences in the probability of
survival.
Risk of CKD
Bariatric surgery showed remarkable protective effect against
crude CKD in the full cohort and in the adjusted matched
group. In the full cohort, patients whom had been treated with
bariatric surgery had 47% lower risk to develop CKD com-
pared to non-bariatric patients (adjusted hazard ratio (aHR):
0.53, 95%CI: 0.30–0.91, P = 0.021). Similarly, the matched
cohort showed a statistical significance of a magnitude
favouring the bariatric group with a protective effect of 54%
against crude CKD risk (aHR: 0.46, 95%CI: 0.24–0.85, P =
0.013). Table 2A shows a summary of adjusted and unadjust-
ed hazard ratios in crude CKD risk for matched and un-
matched patient groups.
Risk of CKD in Patients with Microalbuminuria
Despite a protective tendency against CKD, patients with
microalbuminuria at baseline have little or no statistical evi-
dence of a similar protective effect in the full cohort (aHR:
0.71, 95%CI: 0.33–1.5, P = 0.38). However, the estimates
imply a protective influence against CKD favouring the bar-
iatric group in the matched cohort (aHR: 0.42, 95%CI: 0.18–
0.99, P = 0.050). The adjustments made for this model have
only omitted 13.2% of observed events. Table 2B shows a
summary of adjusted and unadjusted hazard ratios in CKD
risk for patients with microalbuminuria.
Risk of CVD in Patients with Microalbuminuria
In the full cohort, patients with microalbuminuria, who had
been treated with bariatric surgery, had a 70% lower risk in
developing CVD (aHR: 0.30, 95%CI: 0.18–0.96, P = 0.043).
The added adjustments for this model have omitted 37.1% out
of the unadjusted model. However, these adjustments helped
to reveal evidence of little or no statistical effect of such pro-
tection against CVD in the matched cohort (aHR: 0.36,
95%CI: 0.11–1.13, P = 0.079). Table 2C shows a summary
of adjusted and unadjusted hazard ratios in CVD risk for pa-
tients with microalbuminuria.
Change in Secondary Outcome Variables
Significant reductions in the matched cohort (i.e. P < 0.001)
favouring the bariatric group vs non-bariatric were observed
in terms of body weight and BMI throughout 5 years of
follow-up time compared to baseline. Body weight and BMI
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Table 1 Baseline characteristics
Cohort
Full population [N = 11,125] Propensity matched [N = 710]
Baseline variable Bariatric [n = 155] Non-bariatric [n = 10,970] Std. diffa Bariatric [n = 131] Non-bariatric [n = 579] Std. diffb
Demographics
Age (years), mean (SD) 50.01 (11.1) 57.71 (13.3) − 0.694 50.74 (11.0) 51.96 (12.8) − 0.110
Gender, no (%)
Female 89 (57.4) 5068 (46.2) 0.224 73 (55.4) 351 (60.6) − 0.107
Townsend deprivation, %
Least deprived 14.0 21.7 − 0.204 15.7 17.3 − 0.044
Less 24.3 20.7 0.086 24.0 18.1 0.145
Average 17.6 21.4 − 0.094 16.5 20.2 − 0.094
More 20.6 20.9 − 0.008 21.5 27.7 − 0.144
Most deprived 23.5 15.3 0.209 22.3 16.8 0.14
Type 2 diabetes (years), mean (SD)
Diabetes duration 14.15 (7.7) 15.12 (8.4) − 0.125 13.97 (7.8) 14.89 (7.6) − 0.117
Insulin dependency 6.97 (4.9) 7.99 (5.5) − 0.208 7.13 (4.9) 8.55 (5.6) − 0.289
Drug use duration (years), mean (SD)
Oral antidiabetics 11.61 (5.8) 10.77 (6.1) 0.145 11.89 (5.7) 11.26 (5.7) 0.110
Antihypertensive 12.69 (6.6) 12.21 (6.6) 0.074 12.89 (6.7) 12.25 (6.3) 0.095
Diuretics 8.22 (7.3) 8.99 (7.0) − 0.105 8.09 (7.3) 9.32 (7.1) − 0.168
Aspirin 8.34 (5.7) 8.69 (5.4) − 0.061 8.64 (5.9) 8.25 (5.4) 0.066
Clinical parameters, mean (SD)
Weight (kg) 127.3 (30.3) 90.79 (20.6) 1.204 123.22 (28.3) 114.88 (24.5) 0.294
Height (m) 1.7 (0.1) 1.68 (0.1) 0.201 1.7 (0.1) 1.69 (0.1) 0.102
BMI (kg/m2) 43.87 (10.0) 32.37 (7.5) 1.150 42.77 (9.6) 40.6 (9.0) 0.226
HbA1c (mmol/mol) 72.34 (19.3) 70.03 (17.2) 0.119 72.41 (18.6) 70.91 (17.9) 0.080
Fasting glucose (mmol/L) 9.83 (4.3) 9.93 (3.9) − 0.023 9.84 (4.3) 9.82 (3.9) 0.004
Blood glucose (mmol/L) 12.22 (8.8) 11.69 (5.3) 0.071 12.04 (9.1) 11.92 (5.3) 0.016
SBP (mmHg) 134.64 (14.6) 138.89 (16.5) − 0.271 135.06 (14.5) 136.4 (16.0) − 0.088
DBP (mmHg) 78.66 (8.4) 78.94 (9.6) − 0.031 79.3 (8.5) 78.77 (9.3) 0.058
Albumin (g/dL) 3.96 (0.4) 4.15 (0.5) − 0.368 3.96 (0.4) 3.96 (0.4) − 0.005
Alkaline phosphatase (IU/L) 98.31 (47.1) 91.62 (43.0) 0.146 98.79 (48.8) 96.88 (51.5) 0.038
Serum creatinine (μmol/L) 91.74 (78.4) 92.68 (52.6) − 0.014 92.29 (84.0) 88.17 (57.7) 0.056
Triglyceride (mmol/L) 2.33 (1.5) 2.03 (1.3) 0.2 2.34 (1.6) 2.26 (1.4) 0.049
Total cholesterol (mmol/L) 4.47 (1.2) 4.49 (1.1) − 0.019 4.52 (1.2) 4.52 (1.2) 0.002
Low density lipoprotein (mmol/L) 2.39 (0.9) 2.39 (0.9) 0.001 2.39 (0.9) 2.44 (1.0) − 0.05
High density lipoprotein
(mmol/L)
1.07 (0.3) 1.22 (0.4) − 0.439 1.07 (0.3) 1.1 (0.3) − 0.091
Alcohol status, %
Unknown 3.7 3.1 0.03 3.3 3.0 0.017
Ex-drinker 11.8 7.0 0.162 11.6 11.5 0.003
Never 33.1 31.3 0.039 33.1 33.1 − 0.002
Current 51.5 58.5 − 0.143 52.1 52.4 − 0.006
Smoking status, %
Ex-smoker 33.1 37.1 − 0.085 31.4 36.9 − 0.116
Never 52.9 49.7 0.064 52.9 52.2 0.015
Current 14.0 13.1 0.025 15.7 10.9 0.141
Comorbidities, %
Hypoglycaemia 32.4 29.9 0.054 31.3 26.1 0.116
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for bariatric vs non-bariatric were at 1-year point (97.5 ± 24.2
vs 109.8 ± 18.6 kg; 34.2 ± 9.0 vs 38.8 ± 7.4 kg/m2, respec-
tively), at 3-year point (95.7 ± 19.4 vs 108.8 ± 18.4 kg; 33.5 ±
7.4 vs 38.3 kg/m2, respectively) and at 5-year point (98.9 ±
23.3 vs 107.1 ± 18.2 kg; 34.8 ± 9.2 vs 37.8 ± 7.3 kg/m2,
respectively).
The nonparametric tests for the uACR medians revealed
little or no statistical significance of a difference between bar-
iatric and non-bariatric groups in both matched and full co-
horts. In the full cohort, the median uACR in bariatric group at
baseline was 2.0 vs 1.91 mg/mmol in non-bariatric (Z = −
1.28, P = 0.19), at 1-year point 2.33 vs 1.90 mg/mmol (Z =
− 1.86, P = 0.06), and at 2-year point 2.42 vs 2.06 mg/mmol
(Z = − 0.87, P = 0.38), respectively. In the matched cohort, the
median uACR in the bariatric group at baseline was 2.03 vs
1.90 mg/mmol in the non-bariatric group (Z = − 1.75, P =
0.08), at 1-year point 2.31 vs 1.95 mg/mmol (Z = − 1.36, P
= 0.17) and at 2-year point 2.42 vs 2.02 mg/mmol (Z = − 0.67,
P = 0.50), respectively.
There have been significant improvements in eGFR
throughout 5 years of follow-up favouring the bariatric group
in both full and matched cohorts. In the matched cohort, the
eGFR was at similar levels at baseline with a mean of 68.7 in
bariatric patients vs 70.8 mL/min/1.73 m2 in non-bariatric
(t708 = 1.05, P = 0.29). Mean eGFR for the bariatric compared
with non-bariatric group were 72.4 vs 68.4 mL/min/1.73 m2
(t708 = − 2.07, P = 0.038) at 1 year and 71.4 vs 68.4 mL/min/
1.73 m2 (t708 = − 1.48, P = 0.13) at 3 years. However, during
the fourth and fifth years of follow-up, the analysis of mean
differences reported statistical significance favouring the bar-
iatric group versus non-bariatric with 72.9 vs 66.8 mL/min/
1.73 m2 at 4-year point (t708 = − 3.14, P = 0.001) and with
74.2 vs 67.8 mL/min/1.73 m2 at 5-year point, respectively.
Figure 3 illustrates proportions of both bariatric and non-
bariatric patients with eGFR more than 60 mL/min/1.73 m2
during 5 years of follow-up. The serum creatinine was also
significantly reduced in the bariatric group compared to their
matched non-bariatric counterparts during the 2 years of fol-
low-up—following the baseline point. Both groups were at
similar levels of serum creatinine at baseline with a mean of
90.1 (SD 84.1) μmol/L in bariatric versus 88.4 (SD 57.7)
μmol/L non-bariatric (t708 = − 0.27, P = 0.78). Mean creati-
nine for the bariatric group vs non bariatric was 79.7 vs 91.2
μmol/L (t708 = 2.59, P = 0.009) at 6 months, 78.4 vs 86.1
μmol/L (t708 = 2.11, P = 0.03) at 1-year point, and 77.2 vs
90.5 μmol/L at 2-year point (t708 = 2.65, P = 0.008) (Fig. 2c).
In the matched cohort, the bariatric group had significantly
lower albumin levels compared to non-bariatric throughout 2
years of follow-up. The total protein level showed a slight
clinical change with a statistically significant difference at 1-
year point, but with no difference detected in all other points
of follow-up time. Figure 2 shows mean differences between
the matched groups while reflecting back to baseline observa-
tions for (a) total protein and (b) blood albumin.
Discussion
This study focused on severely obese patients with insulin-
treated T2D and noted that there is a relationship between
bariatric surgical intervention and protective effect against
CKD and observed improvements in overall patients’ renal
outcomes, with benefits reaching patients with or without
microalbuminuria at baseline. Despite the matched cohort
showing little or no statistical significance regarding protec-
tion against the risk of non-fatal CVD, the estimates following
the surgery suggest a positive influence with lower event rate
favouring the bariatric group. The survival analysis on full
cohort also indicated a profound effect protecting
microalbuminuria patients who had received bariatric
Table 1 (continued)
Cohort
Full population [N = 11,125] Propensity matched [N = 710]
NAFLDc 4.7 3.0 0.090 4.6 2.8 0.097
Anaemia 15.5 12.2 0.096 16.8 13.3 0.098
Acute myocardial infarction 24.3 20.3 0.095 23.1 20.2 0.073
Stroke 11.0 12.9 − 0.059 12.4 7.7 0.156
Heart failure 18.4 17.8 0.016 17.4 18.5 − 0.029
Diabetes duration is time from first diagnosis of diabetes to date of intensification with insulin drug (index date)
a Standardised differences are the absolute difference in means or percentages divided by the SD of the treated group. Resulting standardised difference
after 1:6 matching based on average treatment effect on treated propensity score technique and robust variance estimation
bMean of standardized difference after matching (0.081), i.e. at 8% difference measured between the matched groups
c Non-alcoholic fatty liver disease
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Fig. 1 Bariatric vs. non-bariatric Kaplan-Meier survival analysis plots for
diagnosed CKD events in a full and b matched cohorts, diagnosed CKD
events in patients with microalbuminuria (i.e. uACR > 3 mg/mmol) at
baseline in c full and d matched cohorts, and crude CVD events in pa-
tients with microalbuminuria at baseline in both e full and f matched
cohorts throughout 10 years of follow-up
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intervention treatment concerning crude non-fatal CVD
events. An overall improvement in the bariatric matched
group regarding eGFR levels was also noted throughout 5
years of follow-up (Fig. 3).
We believe our findings are robust. A review of previously
published studies has shown that we utilised a relatively novel
approach that included an indirect assessment of time-to-event
based on baseline patients’ renal status. This timely phase
involved full, as well as the PS-matched cohorts, being allo-
cated into further stratifications, leading to proper follow-up
for survival investigation. In this approach, the bariatric sur-
gical intervention provides additional evidence of a protective
effect benefiting T2D patients with or without detected
microalbuminuria at baseline.
Obesity is associated with glomerular hyperfiltration, and
therefore increased risk of microalbuminuria and/or protein-
uria in patients with or without renal disease [27, 28]. Previous
studies have shown that bariatric surgery is associated with a
reduction in glomerular hyperfiltration [29, 30] which mainly
occurred in the first year after surgery being associated with
the greatest period of weight loss. The link between fat mass
and glomerular hyperfiltration is multifactorial, but partly due
to increase of angiotensin II (AngII), which enhances tubular
sodium reabsorption and activates tubulo-glomerular feed-
back [31], leading to vasodilation of the afferent arterioles,
with a consequent increase in renal blood flow,
intraglomerular pressure and eGFR [28, 29]. However, while
reductions in glomerular hyperfiltration may induce reduc-
tions in microalbuminuria and proteinuria levels, eGFR is ex-
pected to reduce [32]. There is limited knowledge concerning
the longer-term effect of bariatric surgery on eGFR and CKD
outcomes in patients with insulin-treated T2D. We have spe-
cifically investigated this patient cohort due to the negative
effects of insulin on weight [4], a known predictor of adverse
renal outcomes, as well as the fact that this group of patients
are already at high risk of adverse-cardio-renal outcomes
[5–8]. In addition, patients with diabetes are associated with
accelerated loss of lean muscle mass [33], while bariatric sur-
gery is associated with further loss of muscle mass and func-
tion [34]. Since markers of both muscle mass and strength
being important predictors of outcomes in these patients with
CKD [35], our study provided reassurance of the protective
effects of bariatric surgery against progression of CKD.
The main strength of our study derives from the inclusion
of a relatively large cohort of patients with T2D receiving
insulin therapy who underwent bariatric surgery in a real-
world population. In addition, our database is largely repre-
sentative of the UK population, and as such, our findings will
be generalizable to various populations that share similar de-
mographics. The large cohort of patients studied here provides
adequate statistical power and also contains information on
other time-varying covariates to adjust for possible con-
founders. We adjusted for a large set of factors that could have
differed at baseline. Nonetheless, some residual confounding
in our study could persist. For example, our classification of
albuminuria was largely based on a single measurement, in
contrast to current recommendation, in which at least two
Table 2 Survivability of (A) patients against crude CKD events, (B)
CKD events in patients with microalbuminuria at baseline as well as (C)
CVD events and their respective crude incidence rates and hazard ratios
of events in the full cohort and in the matched group
Survival analysis Non-bariatric Bariatric
A. Crude CKD events
Full cohort, n 9934 139
Events/person-years, n 2032/96,843 16/1283
Absolute ratesa (95% CI) 20.9 (20.1–21.9) 12.5 (7.6–20.3)
HRb (95% CI) 1 (reference) 0.56 (0.33–0.95)†
aHRc (95% CI) 1 (reference) 0.53 (0.30–0.91)†
Matched cohort, n 548 119
Events/person-years, n 103/5385 16/1102
Absolute rates (95% CI) 19.1 (15.8–23.2) 14.5 (8.9–23.7)
HR (95% CI) 1 (reference) 0.67 (0.37–1.22)
aHRd (95% CI) 1 (reference) 0.46 (0.24–0.85)†
B. CKD in patients with microalbuminuria
Full cohort, n 3546 64
Events/person-years, n 775/34,517 8/650
Absolute rates (95% CI) 22.4 (20.9–24.1) 12.3 (6.1–24.6)
HR (95% CI) 1 (reference) 0.59 (0.29–1.20)
aHR (95% CI) 1 (reference) 0.71 (0.33–1.5)
Matched cohort, n 180 53
Events/person-years, n 43/1694 8/558
Absolute rates (95% CI) 25.4 (18.8–34.2) 14.3 (7.2–28.7)
HR (95% CI) 1 (reference) 0.62 (0.28–1.39)
aHR (95% CI) 1 (reference) 0.42 (0.18–0.99)†
C. CVD in patients with microalbuminuria
Full cohort, n 1510 22
Events/person-years, n 710/11,304 10/258
Absolute rates (95% CI) 62.8 (58.3–67.6) 38.7 (20.8–72.0)
HR (95% CI) 1 (reference) 0.70 (0.37–1.34)
aHR (95% CI) 1 (reference) 0.30 (0.09–0.96)†
Matched cohort, n 76 16
Events/person-years, n 33/580 10/202
Absolute rates (95% CI) 56.9 (40.5–80.0) 49.6 (26.7–92.2)
HR (95% CI) 1 (reference) 0.77 (0.34–1.75)
aHR (95% CI) 1 (reference) 0.36 (0.11–1.13)
a Absolute rate at 1000 person-years
b HR (unadjusted hazard ratio)
c aHR (adjusted hazard ration). Adjusted for age, diabetes duration, dura-
tion of antihypertensive drug use, diuretics use, antidiabetic drug use (i.e.
Premix) and deprivation (Townsend) status
d Adjusted for age, diabetes duration and insulin drug use
†P < 0.05 (probability reference)
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measurements are required. Nonetheless, a single measure of
urinary albumin within a large patient cohort provides a great
deal of predictive information. In addition, as is the case in all
studies of CV or ESRD risk associated with eGFR and albu-
minuria, the effect of competing hazards may bias estimates of
risk. This is because elevated ACR and low eGFR are also risk
factors for non-renal diseases, associated differential mortality
in high-risk individuals may confound hazard ratio estimates
for CV events. Lastly, changes after baseline in medications
and subsequent changes in glycaemic indices or blood
Fig. 3 Proportions of patients (%) in the matched cohort with eGFR ≥ 60 (mL/min/1.73 m2) throughout 5 years of follow-up
Fig. 2 Mean change in a total
protein (g/L), b albumin (g/dL),
and c serum creatinine (μmol/L)
in the matched groups, bariatric
vs non-bariatric, compared to
baseline
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pressure were not evaluated in this analysis and, therefore,
cannot account for any differences that might influence the
association between ACR and outcomes.
Although bariatric surgery may protect patients who have
diabetes with or without microalbuminuria against the risk of
CKD, there is a modest protective effect on non-fatal CVD
risk. Bariatric surgery also helps in overall improvement in
renal outcomes such as eGFR. There is, however, a necessity
for prospective investigation and appropriate investment for
verifying or examining real-world effects of bariatric surgical
intervention on renal function and stability of severely obese
patients who are dependent on insulin treatment.
Compliance with Ethical Standards Ethics approval was
provided to THIN by the NHS South East Multi-Centre Research
Ethics Committee (MREC). The Scientific Review Committee (SRC)
reviewed the study protocol for scientific merit and feasibility.
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional,
and global trends in body-mass index since 1980: systematic anal-
ysis of health examination surveys and epidemiological studies
with 960 country-years and 9·1 million participants. Lancet.
2011;377(9765):557–67.
2. Praga M, Morales E. Obesity, proteinuria and progression of renal
failure. Current Opinion in Nephrology and Hypertension.
2006;15(5):481–6.
3. Bays HE. Adiposopathy: is “sick fat” a cardiovascular disease?
Journal of the American College of Cardiology. 2011;57(25):
2461–73.
4. Russell-Jones D, Khan R. Insulin-associated weight gain in diabe-
tes – causes, effects and coping strategies. Diabetes, Obesity and
Metabolism. 2007;9(6):799–812.
5. The Action to Control Cardiovascular Risk in Diabetes Study
Group. Effects of intensive glucose lowering in type 2 Diabetes.
New England Journal of Medicine. 2008;358(24, 2545):–59.
6. Van Avendonk MWJ, Rutten GEH. Insulin therapy in type 2 dia-
betes: what is the evidence? Diabetes. Obesity and Metabolism.
2009;11(5):415–32.
7. Currie CJ, Poole CD, Evans M, et al. Mortality and other important
diabetes-related outcomes with insulin vs other antihyperglycemic
therapies in type 2 diabetes. Journal of Clinical Endocrinology &
Metabolism. 2013;98(2):668–77.
8. Roumie CL, Greevy RA, Grijalva CG, et al. Association between
intensification of metformin treatment with insulin vs sulfonylureas
and cardiovascular events and all-cause mortality among patients
with diabetes. Journal of the American Medical Association.
2014;311(22):2288–96.
9. Levey AS, De Jong PE, Coresh J, et al. The definition, classifica-
tion, and prognosis of chronic kidney disease: a KDIGO
Controversies Conference report. Kidney International.
2011;80(1):17–28.
10. Vidal J. Updated review on the benefits of weight loss. International
Journal of Obesity Related Metabolic Disorders. 2002;26(Suppl 4):
S25–8.
11. Dombrowski SU, Knittle K, Avenell A, et al. Long term mainte-
nance of weight loss with non-surgical interventions in obese
adults: systematic review and meta-analyses of randomised con-
trolled trials. British Medical Journal. 2014;348:g2646.
12. Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight
losing: a meta-analysis in the long- and very long-term effects of
laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y
gastric bypass and laparoscopic sleeve gastrectomy on weight loss
in adults. Surgical Endoscopy. 2017;31(11):4331–45.
13. Stephenson DT, Jandeleit-Dahm K, Balkau B, et al. Improvement
in albuminuria in patients with type 2 diabetes after laparoscopic
adjustable gastric banding. Diabetes and Vascular Disease
Research. 2013;10(6):514–9.
14. Li K, Zou J, Ye Z, et al. Effects of bariatric surgery on renal function
in obese patients: a systematic review and meta analysis. PloS One.
2016;11(10):e0163907.
15. Miras AD, Chuah LL, Khalil N, et al. Type 2 diabetes mellitus and
microvascular complications 1 year after Roux-en-Y gastric bypass:
a case–control study. Diabetologia. 2015;58(7):1443–7.
16. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric
surgery with long-term remission of type 2 diabetes and with mi-
crovascular and macrovascular complications. Journal of the
American Medical Association. 2014;311(22):2297–304.
17. Kim EY, Kim YJ. Does bariatric surgery really prevent deteriora-
tion of renal function? Surgery for Obesity and Related Diseases.
2016;12(4):856–61.
18. Zhou X, Li L, Kwong JS, et al. Impact of bariatric surgery on renal
functions in patients with type 2 diabetes: systematic review of
randomized trials and observational studies. Surgery for Obesity
and Related Diseases. 2016;12(10):1873–82.
19. Chang AR, Grams ME, Navaneethan SD. Bariatric surgery and
kidney-related outcomes. Kidney International Reports.
2017;2(2):261–70.
20. Ben-Porat T, Weiss-Sadan A, Rottenstreich A, et al. Nutritional
management for chronic kidney disease patients who undergo bar-
iatric surgery: A narrative review. Advances in Nutrition.
2019;10(1):122–32.
21. The Heath Improvement Network (THIN). 2018; Available from:
https://www.iqvia.com/locations/uk-and-ireland/thin.
22. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing
and assessing propensity scores. Health Services Research.
2014;49(5):1701–20.
23. Rassen JA, Shelat AA, Myers J, et al. One-to-many propensity
score matching in cohort studies. Pharmacoepidemiology and
Drug Safety. 2012;21(S2):69–80.
24. Austin PC. Statistical criteria for selecting the optimal number of
untreated subjects matched to each treated subject when using
many-to-one matching on the propensity score. American Journal
of Epidemiology. 2010;172(9):1092–7.
25. Morris TP, White IR, Royston P. Tuning multiple imputation by
predictive mean matching and local residual draws. BMC
Medical Research Methodology. 2014;14(1):75.
OBES SURG
26. Eulenburg C, Suling A, Neuser P, et al. Propensity scoring after
multiple imputation in a retrospective study on adjuvant radiation
therapy in lymph-node positive vulvar cancer. PloS One.
2016;11(11):e0165705.
27. De Jong PE, Verhave JC, Pinto-Sietsma SJ, et al. Obesity and target
organ damage: the kidney. International Journal of Obesity &
Related Metabolic Disorders. 2002;26:S21–4.
28. Chagnac A,Weinstein T, Korzets A, et al. Glomerular hemodynam-
ics in severe obesity. American Journal of Physiology-Renal
Physiology. 278(5):F817–22.
29. Changac A, Weinstein T, Herman M, et al. The effects of weight
loss on renal function in patients with severe obesity. Journal of the
American Society of Nephrology. 2003;14(6):1480–6.
30. Serra A, Granada ML, Romero R, Bayés B, Cantón A, Bonet J,
et al. The effect of bariatric surgery on adipocytokines, renal param-
eters and other cardiovascular risk factors in severe and very severe
obesity: 1-year follow-up. Clinical Nutrition. 2006;25(3):400–408.
31. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation
and TGF-β expression in renal glomerular endothelial cells: poten-
tial role in glomerulosclerosis. Kidney International. 1999;56(3):
860–72.
32. Brøchner-Mortensen J, Rickers H, Balslev I. Renal function and
body composition before and after intestinal bypass operation in
obese patients. Scandinavian Journal of Clinical and Laboratory
Investigation. 1980;40(8):695–702.
33. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal
muscle mass in older adults with type 2 diabetes. Diabetes Care.
2009;32(11):1993–7.
34. Skogar M, Holmbäck U, Hedberg J, et al. Preserved fat-free mass
after gastric bypass and duodenal switch. Obesity Surgery.
2017;27(7):1735–40.
35. Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-
energy wasting syndrome in chronic kidney disease: a consensus
statement from the International Society of Renal Nutrition and
Metabolism (ISRNM). Journal of Renal Nutrition. 2013;23(2):77–
90.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
OBES SURG
